EMA's restructured fee model may increase overall burden on drug firms
This article was originally published in Scrip
Executive Summary
The European Medicines Agency is planning to restructure its current fee model so that there is "greater balance" between the money paid by pharmaceutical companies and the level of services provided by the agency. The proposed model, if approved, would effectively do away with the "tailor-made" approach currently being used – a move that has drawn major industry concern as it could increase the overall fee burden on drug companies.